Detailed Information

Cited 250 time in webofscience Cited 278 time in scopus
Metadata Downloads

RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challengesopen access

Authors
Yu, Ai-MingChoi, Young HeeTu, Mei-Juan
Issue Date
Oct-2020
Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
Citation
PHARMACOLOGICAL REVIEWS, v.72, no.4, pp 862 - 898
Pages
37
Indexed
SCIE
SCOPUS
Journal Title
PHARMACOLOGICAL REVIEWS
Volume
72
Number
4
Start Page
862
End Page
898
URI
https://scholarworks.dongguk.edu/handle/sw.dongguk/6075
DOI
10.1124/pr.120.019554
ISSN
0031-6997
1521-0081
Abstract
RNA-based therapies, including RNA molecules as drugs and RNA-targeted small molecules, offer unique opportunities to expand the range of therapeutic targets. Various forms of RNAs may be used to selectively act on proteins, transcripts, and genes that cannot be targeted by conventional small molecules or proteins. Although development of RNA drugs faces unparalleled challenges, many strategies have been developed to improve RNA metabolic stability and intracellular delivery. A number of RNA drugs have been approved for medical use, including aptamers (e.g., pegaptanib) that mechanistically act on protein target and small interfering RNAs (e.g., patisiran and givosiran) and antisense oligonucleotides (e.g., inotersen and golodirsen) that directly interfere with RNA targets. Furthermore, guide RNAs are essential components of novel gene editing modalities, and mRNA therapeutics are under development for protein replacement therapy or vaccination, including those against unprecedented severe acute respiratory syndrome coronavirus pandemic. Moreover, functional RNAs or RNA motifs are highly structured to form binding pockets or clefts that are accessible by small molecules. Many natural, semisynthetic, or synthetic antibiotics (e.g., aminoglycosides, tetracyclines, macrolides, oxazolidinones, and phenicols) can directly bind to ribosomal RNAs to achieve the inhibition of bacterial infections. Therefore, there is growing interest in developing RNA-targeted small-molecule drugs amenable to oral administration, and some (e.g., risdiplam and branaplam) have entered clinical trials. Here, we review the pharmacology of novel RNA drugs and RNA-targeted small-molecule medications, with a focus on recent progresses and strategies. Challenges in the development of novel druggable RNA entities and identification of viable RNA targets and selective small-molecule binders are discussed. Significance Statement-With the understanding of RNA functions and critical roles in diseases, as well as the development of RNA-related technologies, there is growing interest in developing novel RNA-based therapeutics. This comprehensive review presents pharmacology of both RNA drugs and RNA-targeted small-molecule medications, focusing on novel mechanisms of action, the most recent progress, and existing challenges.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Pharmacy > Department of Pharmacy > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Young Hee photo

Choi, Young Hee
College of Pharmacy (Department of Pharmacy)
Read more

Altmetrics

Total Views & Downloads

BROWSE